Hr-positive, her2-negative and pik3ca mutation advanced breast cancer Clinical Trials

Delta Trials tracks 2 clinical trials for Hr-positive, her2-negative and pik3ca mutation advanced breast cancer in its publicly accessible dataset. Among the listed trials, 1 open for participant enrollment and 0 trials have reached completion. This research is carried out at 21 clinical sites around the world. An additional 1 trial have active registrations outside the recruiting and completed categories. This dataset is refreshed continuously as trial statuses are updated on ClinicalTrials.gov, capturing longitudinal changes in the research landscape.